Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will ring the opening bell at the Nasdaq MarketSite in Times Square, New York on Wednesday, August 28, 2024.

“We recently launched Shield, our FDA-approved blood-based screening test, marking a pivotal moment on our journey to conquer cancer with data. We are thrilled to commemorate this important milestone by ringing the Nasdaq bell, nearly six years after we first rang the bell for our IPO,” said AmirAli Talasaz, Guardant Health co-CEO. “Shield offers a more pleasant way to stay up to date with colorectal cancer screening and detect the disease early, when patients have the best chance of survival. This launch is a historic moment for Guardant, the liquid biopsy field, cancer screening, and most importantly, for patients. I’d like to thank our team for their hard work during the last 10 years to bring us here.”

The live broadcast of the Nasdaq Opening Bell ceremony will begin at 8:30 a.m. Eastern Time on Wednesday, August 28, 2024. To view the broadcast, visit: https://www.nasdaq.com/marketsite/bell-ringing-ceremony.

Management will also take part in a Behind the Bell interview from the Nasdaq MarketSite following the opening bell ceremony, which will be available at https://www.nasdaq.com/news-and-insights/behind-the-bell once published.

Company management will be in New York City from August 28 – 29, 2024 for in-person media interviews and investor meetings. Interested parties should contact investors@guardanthealth.com or press@guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240822352380/en/